Home  /  Investors   /  Press releases

Press releases

Here you will find all press releases from XVIVO.

Showing 1 to 30 out of 31 posts.
16 Dec, 2019
XVIVO Perfusion granted Breakthrough Device Designation from the FDA for the XVIVO Heart Preservation System
29 Oct, 2019
Third XPS™ sold in Australia
24 Oct, 2019
Good growth and new important XPS clinics
23 Oct, 2019
XVIVO opens a subsidiary in Australia
23 Oct, 2019
XVIVO Perfusion AB (publ) issue of warrants of series 2019/2021 fully subscribed
21 Oct, 2019
Conference call on Interim Report
24 Sep, 2019
Nomination Committee of XVIVO Perfusion AB (publ)
18 Sep, 2019
XPS™ sold to China
23 Aug, 2019
Lung Bioengineering has acquired the XPS™ for use in its new Jacksonville EVLP center
21 Aug, 2019
Perfadex® Plus has received patent approval in Europe
17 Jul, 2019
XVIVO and MyCartis engage to develop a fast diagnostic test to assess the quality of donated organs before transplantation
12 Jul, 2019
HISTORIC PMA APPROVAL AND PROGRESS IN THE R&D PORTFOLIO
5 Jul, 2019
Conference call on Interim Report
25 Jun, 2019
XVIVO Perfusion changes the date of reporting of the Report on Operations 2019 to January 30, 2020
31 May, 2019
Change in number of shares and votes in XVIVO Perfusion
15 May, 2019
XVIVO has received approval from the Swedish MPA to begin clinical studies with the company’s new products for heart preservation
3 May, 2019
First XPS™ sold to Canada
2 May, 2019
XVIVO’s patents for the heart preservation fluid approved in the US and Europe
29 Apr, 2019
XVIVO has received market approval (PMA) from the FDA for STEEN Solution™ and XPS™
26 Apr, 2019
XVIVO has received market approval (PMA) from the FDA for STEEN Solution™ and XPS™
25 Apr, 2019
Report from Annual general meeting of XVIVO Perfusion AB (publ)
24 Apr, 2019
STRONG GROWTH IN WARM PERFUSION AND PROGRESS IN THE R&D PORTFOLIO
23 Apr, 2019
Results from the heart preservation study presented on ISHLT
16 Apr, 2019
Conference call on Interim Report
2 Apr, 2019
Annual Report 2018
25 Mar, 2019
AMENDMENT OF NOTICE TO ATTEND ANNUAL GENERAL MEETING OF XVIVO PERFUSION AB (publ)
25 Mar, 2019
CEO Magnus Nilsson has the same number of shares as before March 6, 2019
20 Mar, 2019
Annual General Meeting of XVIVO Perfusion AB (publ)
8 Feb, 2019
XVIVO Perfusion AB (publ) Report on operations 2018
4 Feb, 2019
Conference call on Report on Operations

Fill out the form to watch the video